BRPI1100012A2 - agente para realçar a expressão de fatores associados com redox - Google Patents

agente para realçar a expressão de fatores associados com redox

Info

Publication number
BRPI1100012A2
BRPI1100012A2 BRPI1100012A BRPI1100012A BRPI1100012A2 BR PI1100012 A2 BRPI1100012 A2 BR PI1100012A2 BR PI1100012 A BRPI1100012 A BR PI1100012A BR PI1100012 A BRPI1100012 A BR PI1100012A BR PI1100012 A2 BRPI1100012 A2 BR PI1100012A2
Authority
BR
Brazil
Prior art keywords
redox
agent
factors associated
enhance expression
enhancing expression
Prior art date
Application number
BRPI1100012A
Other languages
English (en)
Inventor
Jotaro Nakanishi
Misato Sugahara
Saw W Lee
Yuji Katsuta
Original Assignee
Shiseido Co Ltd
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd, Gen Hospital Corp filed Critical Shiseido Co Ltd
Publication of BRPI1100012A2 publication Critical patent/BRPI1100012A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)

Abstract

"agente para realçar a expressão de fatores associados com redox". a presente invenção refere-se a um agente para realçar a expressão de um fator associado com redox, que compreende caempferol, quercetina ou glicosídeos dos mesmos, ou qualquer combinação dos mesmos como um ingrediente ativo, e um agente para realçar a expressão de um fator associado com redox, que compreende extrato de folha de ginkgo, extrato de kaempferia galanga ou qualquer combinação dos mesmos como um ingrediente ativo.
BRPI1100012A 2010-01-29 2011-01-28 agente para realçar a expressão de fatores associados com redox BRPI1100012A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29958910P 2010-01-29 2010-01-29
PCT/JP2011/051811 WO2011093469A1 (ja) 2010-01-29 2011-01-28 レドックス関連因子発現促進剤

Publications (1)

Publication Number Publication Date
BRPI1100012A2 true BRPI1100012A2 (pt) 2016-05-03

Family

ID=44319447

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1100012A BRPI1100012A2 (pt) 2010-01-29 2011-01-28 agente para realçar a expressão de fatores associados com redox

Country Status (9)

Country Link
US (1) US20110189318A1 (pt)
EP (1) EP2529736A4 (pt)
JP (1) JP5833438B2 (pt)
KR (1) KR20120119976A (pt)
CN (1) CN102361637A (pt)
BR (1) BRPI1100012A2 (pt)
RU (1) RU2606856C2 (pt)
TW (1) TWI572353B (pt)
WO (1) WO2011093469A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU91412B1 (en) * 2008-01-30 2009-07-31 Wurth Paul Sa Charging device for distributing bulk material
JP2016006021A (ja) * 2014-06-20 2016-01-14 株式会社ノエビア チオレドキシン関連因子発現促進剤
JP2016088905A (ja) * 2014-11-07 2016-05-23 健治 椛島 上皮又は粘膜に投与される組成物
JPWO2016132483A1 (ja) * 2015-02-18 2017-11-24 学校法人福岡大学 ヒトキマーゼ阻害剤及びヒトキマーゼの活性が関与する疾患の予防治療用薬剤
JPWO2022075096A1 (pt) * 2020-10-07 2022-04-14
JP6860739B1 (ja) * 2020-11-20 2021-04-21 ジェイ−ネットワーク，インコーポレイテッド 表皮内の抗酸化物質の発現増強剤
WO2022233922A1 (en) * 2021-05-06 2022-11-10 Société des Produits Nestlé S.A. Compositions and methods using at least one of inositol, erythritol or sorbitol to enhance growth of faecalibacterium prausnitzii
JP2024031635A (ja) * 2022-08-26 2024-03-07 株式会社 資生堂 可視光によりフラボノイドの生理作用を増強するための美容方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0769862A (ja) * 1993-09-01 1995-03-14 Kao Corp 入浴剤組成物
JP3578858B2 (ja) 1995-12-11 2004-10-20 株式会社ノエビア 皮膚外用剤
US6471972B1 (en) * 1996-11-07 2002-10-29 Lvmh Recherche Cosmetic treatment method for fighting against skin ageing effects
US20040043047A1 (en) * 1999-03-26 2004-03-04 Parfums Christian Dior Cosmetic or dermatological compositions containing at least one substance for increasing the functionality and/or expression of the CD44 membrane receptors of skin cells
US20040101578A1 (en) * 2001-08-03 2004-05-27 Min-Young Kim Compositon containg ginkgo biloba that inhibit angiogenesis and matrix metalloprotinase
EP1684774B1 (en) * 2003-11-05 2012-08-29 Osteoscreen, Inc. Stimulation of hair growth by isoginkgetin
WO2006033351A1 (ja) 2004-09-22 2006-03-30 Kyoto University チオレドキシン発現誘導用組成物
KR20060080376A (ko) * 2005-01-05 2006-07-10 하수용 무기 광물 용해액 및 식물 추출물을 포함하는 화장료조성물 및 그의 제조 방법
US20060165812A1 (en) * 2005-01-21 2006-07-27 Amershire Investment Corporation Method and topical formulation for treating headaches
KR100665966B1 (ko) * 2005-09-23 2007-01-09 장정만 규산염과 은행잎추출물로 제조되는 입욕제의 조성물 및제조제법
JP2007284430A (ja) 2006-03-20 2007-11-01 Rohto Pharmaceut Co Ltd グルタチオン産生促進剤
JP2007269671A (ja) 2006-03-30 2007-10-18 Redox Bioscience Inc アレルギー性皮膚炎の予防ないし治療剤
KR100892273B1 (ko) * 2007-04-25 2009-04-09 (주)아모레퍼시픽 캄페롤-3-ｏ-루티노사이드를 유효 성분으로 함유하는 피부외용제 조성물
JP2009132662A (ja) * 2007-11-30 2009-06-18 Maruzen Pharmaceut Co Ltd グルタチオン産生促進剤

Also Published As

Publication number Publication date
JP5833438B2 (ja) 2015-12-16
RU2606856C2 (ru) 2017-01-10
TW201136587A (en) 2011-11-01
KR20120119976A (ko) 2012-11-01
CN102361637A (zh) 2012-02-22
EP2529736A1 (en) 2012-12-05
WO2011093469A1 (ja) 2011-08-04
US20110189318A1 (en) 2011-08-04
RU2011134486A (ru) 2013-02-27
JPWO2011093469A1 (ja) 2013-06-06
TWI572353B (zh) 2017-03-01
EP2529736A4 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
BRPI1100012A2 (pt) agente para realçar a expressão de fatores associados com redox
BR112012006692A2 (pt) composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas
UA118177C2 (uk) Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну
BR112012024349A2 (pt) métodos de tratamento de carcinoma hepatocelular
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112013000537A2 (pt) composição aquosa contendo bromexina
BR112015008759A2 (pt) método para a profilaxia e/ou tratamento de sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, agente profilático e/ou terapêutico para sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, uso de um composto, composto, e, composição farmacêutica
BR112015007183A2 (pt) composições, uso de uma composição, método para o combate dos fungos e semente
BRPI1009842B8 (pt) uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas
BR112014030655A8 (pt) Compostos inibidores de pirimidinil tirosina quinase, e composição farmacêutica que os compreende
GT200800123A (es) Compuestos mimeticos de lisina modificados
MX380318B (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
BR112014016649A2 (pt) composições para tratamento dos cabelos
BR112012024442A2 (pt) métodos de tratamento de câncer
CU23815A3 (es) Diarilureas para el tratamiento de hipertensión pulmonar
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112013019394A2 (pt) uso de um agente
CL2011002617A1 (es) Compuestos derivados de arilsulfonamidas 2,5-disustituidas, moduladores del receptor ccr3; composicion farmaceutica que los comprende; y uso del compuesto o de la composicion para prevenir y/o tratar un trastorno inflamatorio o inmunoregulador tal como asma, rinitis, vih, enfermedad de alzheimer, entre otros.
BR112012015084A2 (pt) composição farmacêutica de liberação lenta de iloperidone
FR2969924B1 (fr) Composition comprenant un phosphate de tocopherol
EA201101126A1 (ru) Фармацевтическая композиция и способ увеличения роста волос
BRPI0815455C1 (pt) compostos derivados de n-fenilacetamida, composição farmacêutica, composição cosmética, uso cosmético de uma composição, e usos de um composto do mesmo

Legal Events

Date Code Title Description
B15L Others concerning applications: renumbering

Free format text: RENUMERADO O PEDIDO DE PI1100012-0 PARA PP1100012-0.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2498 DE 21-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.